ESC-HFA 2023: Late-Breaking Science Video Collection

Published: 23 May 2023

Views:
2896
Likes:
7

Views:
2896
Likes:
7
Share:

Now Playing
Part 2 | Session 4 of 10
DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction
Ankeet Bhatt

Up Next
8m 47s

Part 2 | Session 5 DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF
Domingo Figal
4m 53s

Part 2 | Session 6 NUDGE-FLU: Increasing Influenza Vaccination in HF Patients
Niklas Dyrby Johansen
3m 56s

Part 2 | Session 7 DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF
Ross Campbell
5m 11s

Part 2 | Session 8 TRANSFORM-HF: Torsemide Vs Furosemide on Quality of Life in Heart Failure
Stephen J Greene
8m 22s

Part 2 | Session 9 Diagnosis in Heart Failure in Women
John GF Cleland
3m 50s

Part 2 | Session 10 Dapagliflozin and Peripheral Arterial Disease in Heart Failure
Jawad Haider Butt

26m 30s

Part 1 | Session 1 Hospital to Home in HF: Insights from ACT-HF, PROMPT-AHF & STRONG-HF Kidney Harriette Van Spall, Tariq Ahmad, Jozine ter Maaten

5m 48s

Part 1 | Session 2 The PARAGLIDE-HF Trial Harriette Van Spall, Robert Mentz

13m 32s

Part 1 | Session 3 HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi Harriette Van Spall, James L Januzzi

4m 3s

Part 1 | Session 4 TRACER-HF: Trientine-HCL for Treatment of Heart Failure and Reduced Ejection Fraction James L Januzzi, Harriette Van Spall

2m 45s

Part 2 | Session 1 MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring Jasper J Brugts

6m 54s

Part 2 | Session 2 REDWOOD-HCM-Cohort 4: Aficamten in Non-obstructive Hypertrophic Cardiomyopathy Ahmad Masri

3m 11s

Part 2 | Session 3 APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis Marianna Fontana

Average (ratings)

No ratings

Your rating

Overview

Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023.

Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series.

For concise and practical take-home messages for practice and cardiovascular research watch our 5-minute Expert Interviews conducted with investigators.

Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of HFA 2023.

More from this programme

Part 1

Late-breaker Discussions with Dr Van Spall

4 sessions
Hospital to Home in HF: Insights from ACT-HF, PROMPT-AHF & STRONG-HF Kidney	Watch now
The PARAGLIDE-HF Trial	Watch now
HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi	Watch now
TRACER-HF: Trientine-HCL for Treatment of Heart Failure and Reduced Ejection Fraction	Watch now

Part 2

Expert Interviews

10 sessions
MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring	Watch now
REDWOOD-HCM-Cohort 4: Aficamten in Non-obstructive Hypertrophic Cardiomyopathy	Watch now
APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis	Watch now
DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction	Watch now
DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF	Watch now
NUDGE-FLU: Increasing Influenza Vaccination in HF Patients	Watch now
DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF	Watch now
TRANSFORM-HF: Torsemide Vs Furosemide on Quality of Life in Heart Failure	Watch now
Diagnosis in Heart Failure in Women	Watch now
Dapagliflozin and Peripheral Arterial Disease in Heart Failure	Watch now

About the episode

Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, US) joins us to discuss a study that looked into Kansas City Cardiomyopathy Questionnaire (KCCQ) scores in patients with varying ejection fractions, that were enrolled in the DELIVER and DAPA-HF trials.

This study used pooled, patient-level data from the DAPA-HF and DELIVER studies, aiming to examine the impact effects of dapagliflozin health status across the full spectrum of LVEF.

Results suggest that dapagliflozin improved health status as measured by KCCQ scores at both 4 and 8 months post-randomization. These improvements were consistently observed across the full spectrum of LVEF.

Interview Questions:

What was the reasoning behind comparing the DAPA-HF and DELIVER Trials?
What is the current landscape of research into dapagliflozin in 2023?
What was the study design and patient cohort?
What are the key findings?
How does this analysis shed new light on the findings of both DAPA and DELIVER?
How should the results of this study be applied to clinical practice?
What further study is needed?